ArticleNature communications2021
Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 87 citations in OpenAlex.
- Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trial.Journal for immunotherapy of cancer · 2025Trial
- Analysis of the Safety and Efficacy of Cryoablation in Patients with Locally Advanced Pancreatic Cancer.Annals of surgical oncology · 2026Article
- Beyond Tumor Treating Fields: Multimodal Antitumor Action and the Clinical Potential of Pulsed Electromagnetic Fields.Current medical science · 2026Review
- Ablation-immunotherapy synergy in cancer: mechanisms of the abscopal effect, emerging clinical applications, and translational roadmaps for next-generation onco-immunology.Medical oncology (Northwood, London, England) · 2026Review
- Targeting regulatory T cells in the prostate cancer microenvironment: From mechanisms to therapeutics (Review).Molecular medicine reports · 2026Review
- Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Irreversible electroporation in focal therapy for prostate cancer: current status and future directions.Prostate international · 2026Review
- First-in-human single-cell and TCR atlas reveals peripheral immune remodeling before and after irreversible electroporation in prostate cancer.Journal for immunotherapy of cancer · 2026Article
- Cellular fragmentation underlies the immunogenicity of irreversible electroporation-mediated tumor cell killing.Bioengineering & translational medicine · 2026Article
- Synergistic immunotherapeutic effects of irreversible electroporation and CAR-NK cell therapy against hepatocellular carcinoma.Signal transduction and targeted therapy · 2026Article
- Irreversible electroporation for localized prostate cancer: risk-stratified oncologic outcomes and functional preservation.Prostate international · 2026Article
- Irreversible electroporation in prostate cancer: efficacy, tumor immune microenvironment remodeling, and combination immunotherapy-a narrative review.Translational andrology and urology · 2026Review
- Inhibiting Effect of Inner Potential on Electroporation of Phospholipid Membranes Induced by Ionic Electrophoresis.International journal of molecular sciences · 2026Article
- Novel Combination of Irreversible Electroporation and Allogenic Chimeric Antigen Receptor T-Cell Therapy Synergizes Therapeutic Outcomes in a Preclinical Human Pancreatic Cancer Mouse Model.Research (Washington, D.C.) · 2026Article
- Translating physical stress into biological signals: precision electro-oncology based on conformational changes of electro-sensitive receptors and parameterized immune remodeling.Frontiers in oncology · 2026Review
- Experimental study on synergistic pulses improving the tumor microenvironment and assisting immunotherapy.Frontiers in immunology · 2026Article
- CD40 agonist improves the therapeutic efficacy of irreversible electroporation ablation for metastatic melanoma by promoting unexpected CD8Cancer immunology, immunotherapy : CII · 2025Article
- The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives.Journal of hematology & oncology · 2025Review
- Nanostrategies synergize with locoregional interventional therapies for boosting antitumor immunity.Bioactive materials · 2025Article
- Calcium Electrochemotherapy and Challenges in Combined Treatment with Dendritic Cell Vaccination.Pharmaceutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Brandon J Burbach *Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA. burba005@umn.edu.ORCID 0000-0003-0922-7722
Stephen D O'Flanagan *Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-9286-1208
Qi Shao *Masonic Cancer Center, University of Minnesota, Minneapolis, USA.ORCID 0000-0002-8190-1067
Katharine M YoungDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0001-5294-209X
Joseph R SlaughterDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-3713-1851
Meagan R RollinsDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Tami Jo L StreetDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-7226-1352
Victoria E GrangerDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Lalit K BeuraCenter for Immunology, University of Minnesota, Minneapolis, USA.ORCID 0000-0002-8597-3949
Samira M AzarinMasonic Cancer Center, University of Minnesota, Minneapolis, USA.ORCID 0000-0003-0395-4988
Satish RamadhyaniBTG plc, Arden Hills, MN, USA.ORCID 0000-0002-1966-198X
Bruce R ForsythBoston Scientific Corporation, Maple Grove, MN, USA.
John C BischofMasonic Cancer Center, University of Minnesota, Minneapolis, USA.
Yoji ShimizuDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA. shimi002@umn.edu.ORCID 0000-0001-9760-0288
University of Minnesota · USBoston Scientific (United States) · US
Funding
Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4MIntegrin regulation of memory CD8 T cellsR21AI123600 · NIAID · UNIVERSITY OF MINNESOTA · PI SHIMIZU, YOJI · 2016 to 2017
$419kNCI NIH HHS P30 CA077598NIAID NIH HHS R21 AI123600
Abstract
Memory CD8+ T cells populate non-lymphoid tissues (NLTs) following pathogen infection, but little is known about the establishment of endogenous tumor-specific tissue-resident memory T cells (T
Indexed as
AnimalsAntigens, NeoplasmCD8-Positive T-LymphocytesCell Line, TumorDisease Models, AnimalElectroporationHumansImmune Checkpoint InhibitorsImmunologic MemoryImmunotherapyKaplan-Meier EstimateMaleMiceMice, Inbred C57BLMice, TransgenicProstatic NeoplasmsAntigens, NeoplasmImmune Checkpoint Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.